MoleculeMind Achieves Breakthrough in AI-Powered Nanobody Design with MMDesign Platform
MoleculeMind has announced a significant advancement in AI-driven biologics design using its MMDesign platform. The platform has demonstrated a success rate exceeding 90% in de novo nanobody design. This breakthrough was achieved by Professor Xu Jinbo, a notable figure in AI protein folding research. AI
IMPACT Accelerates drug discovery and development pipelines by enabling rapid, high-success-rate design of novel biologics.